ストックスクリーナーアプリを入手
6.98
0.99%
-0.07
アフターアワーズ：
7.00
0.02
+0.29%
前日終値:
$7.05
開ける：
$7.08
24時間の取引高:
12,996
Relative Volume:
0.84
時価総額：
$19.39M
収益：
$22.03M
当期純損益:
$-19.91M
株価収益率:
-0.377
EPS:
-18.5137
ネットキャッシュフロー:
$-16.84M
1週間 パフォーマンス:
+9.06%
1か月 パフォーマンス:
-5.42%
6か月 パフォーマンス:
+1.44%
1年 パフォーマンス:
-53.84%
1日の値動き範囲:
$6.3972
$7.08
1週間の範囲:
$6.0001
$7.21
52週間の値動き範囲:
$4.14
$15.24
Lifeward Ltd Stock (LFWD) Company Profile
Compare LFWD vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LFWD
Lifeward Ltd
|
6.98 | 19.59M | 22.03M | -19.91M | -16.84M | -18.51 |
ABT
Abbott Laboratories
|
86.67 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
313.00 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.60 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.64 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.54 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Lifeward Ltd Stock (LFWD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-10 | 開始されました | Laidlaw | Buy |
| 2017-04-03 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2016-12-16 | 開始されました | Oppenheimer | Outperform |
| 2016-07-15 | 開始されました | Piper Jaffray | Overweight |
| 2015-05-22 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2015-05-08 | 繰り返されました | Barclays | Equal Weight |
| 2014-10-07 | 開始されました | Barclays | Equal Weight |
すべてを表示
Lifeward Ltd (LFWD) 最新ニュース
H.C. Wainwright Maintains Lifeward(LFWD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Lifeward (LFWD) Q4 2025 Earnings Transcript - AOL.com
LFWD Technical Analysis | Trend, Signals & Chart Patterns | LIFEWARD LTD (NASDAQ:LFWD) - ChartMill
Lifeward’s Earnings Call Balances Setbacks and Strategy - The Globe and Mail
Lifeward (Nasdaq: LFWD) posts wider Q1 loss, adds Oratech and new convertible debt - Stock Titan
Lifeward (LFWD) Chief Medical Officer receives 15,000-share RSU award - Stock Titan
Lifeward (LFWD) Chief Medical Officer discloses 2,083 ordinary shares - Stock Titan
Lifeward promotes Keith Rose to chief medical officer By Investing.com - Investing.com Nigeria
Lifeward Ltd. Appoints Keith D. Rose, M.D. as Chief Medical Officer – SEC 8-K Filing May 2026 - Minichart
Lifeward appoints Keith D. Rose, M.D. as chief medical officer By Investing.com - Investing.com Australia
Lifeward appoints Keith D. Rose, M.D. as chief medical officer - Investing.com
Lifeward Names Keith D. Rose as Chief Medical Officer - TipRanks
Lifeward (NASDAQ: LFWD) appoints Keith D. Rose, M.D. as new CMO - Stock Titan
Lifeward promotes Keith Rose to chief medical officer - Investing.com
Lifeward Appoints Dr. Keith D. Rose as Chief Medical - GlobeNewswire
Lifeward Ltd.16079622026 - SEC.gov
Lifeward (LFWD) price target decreased by 37.93% to 4.59 - MSN
How The Lifeward (LFWD) Story Is Shifting With New Price Targets And Valuation Assumptions - Yahoo Finance
Lifeward Ltd (LFWD) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing Growth Opportunities - GuruFocus
Number of shareholders of Lifeward Ltd. – BOATS:LFWD - TradingView
Lifeward Earnings Call Balances Growth With Disruptions - TipRanks
Lifeward Q1 earnings preview - MSN
Earnings Call Summary | Lifeward(LFWD.US) Q1 2026 Earnings Conference - 富途牛牛
Lifeward 1Q Loss/Shr $6.70 >LFWD - Moomoo
Lifeward Q1 2026 Loss Deepens: -$3.13/Share vs -$0.34 Expected - AlphaStreet
Lifeward Ltd (LFWD) Q1 2026 Earnings Miss: EPS -$6.70 vs -$1.26 - GuruFocus
Lifeward (LFWD) Q1 2026 Earnings Transcript - AOL.com
Lifeward expects 2026 revenue similar to 2025 following Oratech acquisition and $10M convertible note financing - MSN
Lifeward Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance
Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates - sharewise.com
Lifeward Ltd. Closes Oratech Acquisition, Receives $10M Financing, Launches Phase 2 Oral Insulin Trial, and Expands Exoskeleton Technology for Stroke Rehabilitation - Minichart
Transcript : Lifeward Ltd., Q1 2026 Earnings Call, May 15, 2026 - marketscreener.com
Lifeward Ltd (NASDAQ:LFWD) Q1 Revenue Misses Estimates as Strategic Transformation Takes Shape - ChartMill
Lifeward Delays Quarterly Report Amid Deal Accounting - TipRanks
Lifeward Releases Q1 2026 Financial Results - AlphaStreet
LFWD: Q1 revenue fell on AlterG delays, but ReWalk sales and liquidity improved with new acquisitions - TradingView
Earnings call transcript: Lifeward’s strategic moves amid Q1 2026 challenges - Investing.com
LFWD: Revenue fell on AlterG delays, but ReWalk sales and liquidity improved; outlook remains stable - TradingView
Lifeward Q1 2026 Earnings Call Transcript - Benzinga
Lifeward: Q1 Earnings Snapshot - WKYC
[NT 10-Q] Lifeward Ltd. SEC Filing - Stock Titan
Lifeward 1Q Rev $3.92M >LFWD - Moomoo
Press Release: Lifeward Reports First Quarter 2026 Financial Results - Moomoo
Lifeward (Nasdaq: LFWD) posts Q1 2026 loss and boosts cash via deals - Stock Titan
Stroke exoskeleton and oral insulin headline Lifeward Q1 - Stock Titan
Oramed Pharmaceuticals Discloses Investment at Lifeward with 49.9% Stake - TradingView
Oramed details Lifeward (LFWD) equity stake, notes and warrants - Stock Titan
Oramed (LFWD) reports 49.9% Lifeward stake, $9M notes and warrants - Stock Titan
Walk Assist Robot Market Research Report 2026-2031: Leading firms Such as Ekso Bionics, Lifeward, Cyberdyne, Ottobock, and DIH Medical Lead the $568.81 Million Market - Yahoo Finance
Lifeward Ltd expected to post a loss of $1.25 a shareEarnings Preview - TradingView
TradingKey - TradingKey
Lifeward Ltd (LFWD) 財務データ
収益
当期純利益
現金流量
EPS
1.27%
2.05%
大文字化:
|
ボリューム (24 時間):